Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Mar 18;9(3):e001865. doi: 10.1136/jitc-2020-001865

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/.

PMC Copyright notice

Primary endpoint: most common treatment-related SAEs and irAEs (in ≥2 patients) by CTCAE grade. (A) Treatment-related SAEs and (B) treatment-related irAEs. ^aAdverse events were defined as serious if they were fatal, were life threatening, required hospitalization, resulted in disability, or resulted in a congenital birth defect in an infant born to a mother exposed to study drug. ^birAEs were defined as any adverse event of special interest requiring corticosteroid treatment within 30 days of onset. ALT, alanine aminotransferase; AST, aspartate aminotransferase; CTCAE, Common Terminology Criteria for Adverse Events; irAEs, immune-related adverse events; IRR, infusion-related reaction; SAE, serious adverse event.